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ABSTRACT
There is a critical unmet clinical need for bladder cancer immunotherapies capable of inducing durable
antitumor immunity. We have shown that four intravesical treatments with a simple co-formulation of
interleukin-12 and the biopolymer chitosan not only destroy orthotopic bladder tumors, but also promote
a potent long-lasting systemic immune response as evidenced through tumor-specific in vitro killing
assays, complete protection from rechallenge, and abscopal antitumor responses at distant non-treated
tumors. This study investigates the immunological kinetics underlying these results. We show through
depletion studies that CD8C T cells are required for initial tumor rejection, but CD4C T cells protect against
rechallenge. We also show that even a single intravesical treatment can eliminate tumors in 50% of mice
with 6/9 and 7/8 mice eliminating tumors after three or four treatments respectively. We then performed
immunophenotyping studies to analyze shifts in immune cell populations after each treatment within the
tumor itself as well as in secondary lymphoid organs. These studies demonstrated an initial infiltration of
macrophages and granulocytes followed by increased CD4C and CD8C effector-memory cells. This was
coupled with a decreased level of regulatory T cells in peripheral lymph nodes as well as decreased
myeloid-derived suppressor cell infiltration in the bladder. Taken together, these data demonstrate the
ability of properly delivered interleukin-12-based therapies to engage adaptive immunity within the tumor
itself as well as throughout the body and strengthen the case for clinical translation of chitosan/
interleukin-12 as an intravesical treatment for bladder cancer.
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Introduction
In the United States alone more than 76,000 new cases of blad-
der cancer are expected this year with more than 16,000 deaths
associated with the disease.1,2 The majority of new cases are
of non-muscle invasive disease, accounting for 70–80% of
diagnoses.3 For 40 y, the standard of care for high-grade, non-
muscle invasive disease has been intravesical therapy withMyco-
bacterium bovis bacillus Calmette–Guerin (BCG) after a trans-
urethral resection of the tumor. Despite years of clinical
immunotherapy with BCG, a specific antitumor memory
response as a result of BCG therapy has not been demonstrated.4
This has led to bladder cancer recurrence rates of 50–80%, the
highest of any major malignancy.5 Although there has been
recent progress in treatment of some metastatic cases with
checkpoint inhibitors,6 there remains an urgent need for novel
treatments for both muscle invasive and early stage disease.
Our laboratory has developed an immunotherapy composed
of interleukin-12 co-formulated with the biopolymer chitosan
(CS/IL-12).7-9 In CS/IL-12 immunotherapy, IL-12 acts as a
powerful immune stimulant, whereas chitosan enhances IL-12’s
penetration into the urothelium.7 Interleukin-12 is a TH1 polar-
izing cytokine, capable of reversing an immunosuppressive
environment within tumors. We have shown that four intraves-
ical instillations of CS/IL-12 not only eliminate up to 90% of
bladder tumors in two orthotopic murine bladder tumor mod-
els, but also induce a powerful memory response capable of
complete systemic protection that remains durable for the
remaining lifespan of the mice.7,9 We have also shown that a
similar co-formulation delivered intratumorally has potent
effects against other tumors of non-bladder origin.8,10,11 But the
immunological mechanisms underlying this effectiveness, espe-
cially with regards to bladder tumors have not been elucidated.
A number of studies have shown that IL-12-based therapies
delivered intratumorally act in an IFNg dependent manner to
increase CD3C, CD4C, and CD8C T-cell infiltration while
activating existing tumor infiltrating lymphocytes (TILs) and
reducing the frequencies of regulatory T cells (TRegs) and
myeloid-derived suppressor cells (MDSC).8,12,13 However, the
means by which IL-12 induces an effective immune response
varies by tumor type and even by the same tumor type in
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different tissues.14 Furthermore, the kinetics of an IL-12-based
immunotherapy within the bladder has not been documented.
The purpose of the current study is to build on our knowl-
edge of IL-12-based therapies by asking three questions regard-
ing the immunological mechanisms and kinetics of intravesical
CS/IL-12. First, which immune cells are most vital to both the
initial treatment and the subsequent protection? Second, what
is the effect of number of treatments on elimination of bladder
tumors? Third, how does the response to intravesical CS/IL-12
immunotherapy evolve throughout the course of treatment
both at the treatment site and in secondary lymphoid organs?
Results
Initial tumor rejection is primarily driven by CD8C T cells
To determine the role of immune cell subsets on the efficacy of
intravesical CS/IL-12 immunotherapy, we depleted tumor-
bearing mice of CD4C, CD8C, or NK1.1C cells prior to
treatment. Each cell type was revealed to play a role in the
effectiveness of CS/IL-12 immunotherapy with 4/8 NK-
depleted, 4/8 CD4C-depleted, 0/9 CD8C-depleted, mice
surviving tumor free (Fig. 1A). In contrast, 7/9 mice that were
not depleted completely eliminated their tumors. Despite all
succumbing to their tumors, mice depleted of CD8C cells
experienced extended median survival by 6 d when compared
with phosphate buffered saline (PBS) treated mice (p < 0.05).
All other treated mice regardless of depletion status also
extended survival (p < 0.05) beyond PBS treated as well as
CD8C T-cell depleted mice.
The memory response is dependent on CD4C T cells
We have previously shown that mice that have eliminated their
orthotopic bladder tumors after treatment with CS/IL-12 were
able to reject subsequent tumor rechallenge even at a distant (sub-
cutaneous) site.9 To identify the immune cell subtypes required
for this systemic memory, we depleted immune cell subsets in
mice which had previously eliminated their tumors and then
rechallenged them subcutaneously in the right flank with MB49
(Fig. 1B). All (4/4) non-depleted mice rejected rechallenge and all
naive mice (12/12) grew tumors. Depletion of NK cells had little
effect on tumor protection with 4/5 mice rejecting their rechal-
lenge. Surprisingly, depletion of CD8C cells also had a minimal
effect with 81% (13/16) mice rejecting rechallenge. The main
effectors of the subsequent rejection were found to be CD4C cells
with only 1/9 mice rejecting rechallenge. Non-depleted, CD8C
depleted, and NK1.1C depleted groups were all significantly differ-
ent (p< 0.05) than both naive and CD4C depleted groups.
Number of treatments impact tumor rejection
The decision to use four intravesical treatments of CS/IL-12 in
our previous publications was largely determined through
experimental observation. Nearly all treated mice tend to be
hematuria free after the fourth treatment. We sought to better
explore the significance of the number of administrations by
applying either 1, 2, 3, or 4 treatments while tracking survival
(Fig. 2). As expected, mice given the full course of four
treatments showed the greatest ability to eradicate their tumors
with 7/8 surviving long term. However, fewer treatments were
also effective with 6/9, 2/7, and 4/8 mice surviving long term
when given 3, 2, or 1 treatment respectively. All curves were
significantly different than PBS treated controls (p < 0.005)
and both 3 and 4 treatments were significantly different than
two treatments (p < 0.005) but were not statistically different
than a single treatment. However, giving three or four treat-
ments did significantly prolong survival over 1 or 2 treatments
(p < 0.05) (Fig. 2B).
In a separate experiment, bladders were harvested 1 d after
each treatment, weighed (Fig. 3A) and photographed (Fig. 3B).
Bladder weight in CS/IL-12 treated mice began to separate
from PBS controls (p D 0.056) by the third treatment. Bladders
of CS/IL-12 treated mice were significantly smaller
(p < 0.0005) after the fourth treatment. There was also a
noticeable difference in the volume and redness of the bladders
by the third treatment as seen in Fig. 3B.
Treatment number affects immune cell infiltration locally
and systemically
Since the number of treatments impacts the therapeutic efficacy
of intravesical CS/IL-12, we decided to perform a study of the
immune kinetics over the full course of treatment. We also
knew from previous studies that an intravesical treatment of
CS/IL-12, though confined to the bladder, induces a systemic
immune response capable of eliminating distant tumors.4 To
characterize this response, we performed a time-course study
in which the bladder tumors as well as the spleen and bladder-
draining lymph nodes (BDLNs) were harvested 24 h after each
treatment and analyzed for shifts in a number immune cell
populations via flow cytometry (Fig. S2). All results are of 4–5
mice from duplicate experiments. Statistical comparisons are
either between immune cell populations within the CS/IL-12
and PBS treated groups at the same time point via Student’s
t-test or differences in those populations within the CS/IL-12
treatment group with respect to treatment number as
determined via one-way ANOVA.
Shifts in lymphocyte populations are most pronounced in
the bladder after the third treatment
CD3C Lymphocytes: The proportion of live leukocytes consisting
of CD3C T cells varied by tissue, treatment, and treatment
number. T-cell infiltration in treated mice rose in the bladder
after the third and fourth treatments with mean infiltrations
more than twice that of PBS treated mice (p < 0.05, Fig. 4, first
row). These differences were less pronounced in distant organs
with a small decrease in the spleen from 25.5% (PBS) to 19.5%
(CS/IL-12) after the third treatment (p < 0.05) as well as a slight
increase from 34.6% (PBS) to 41.6% (CS/IL-12) in the BDLNs
at the fourth treatment (p < 0.05). Overall, CS/IL-12 treatment
number affected CD3C infiltration in the bladder (p < 0.05 via
ANOVA), but not in the spleen or BDLNs.
CD4C lymphocytes: CD3CCD4C helper T-cell fluctuation was
most pronounced in the bladder tumors (Fig. 4, second row) and
varied with treatment type as well as treatment number (p < 0.05
via ANOVA). T-cell infiltration initially dropped (perhaps as an
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artifact of intense macrophage and granulocyte inflammation)
before recovering by the third treatment and exceeding that of
PBS treated tumors by a factor of 3 (p < 0.05). There were only
minor effects at distant lymphoid sites with a small drop in the
spleen at the third treatment (p < 0.05). Overall, CS/IL-12 caused
increased CD4C infiltration in the bladder, but not at distant sites
regardless of treatment number.
CD8C lymphocytes: There was a drop in CD3CCD8C cytotoxic
T cells (Fig. 4, third row) in the bladder corresponding with the
first treatment. Similar to CD4C decreases after one treatment,
this may be an artifact of intense monocytic and granulocytic
inflammation. However, an eventual recovery by the second treat-
ment led to levels statistically indistinguishable from PBS treated
mice. There were more substantial effects at the systemic level
with increased infiltration in the BDLNs after the third treatment
as well as the same small drop observed in the spleen for both
CD3C and helper T cells at the third treatment. Overall, CS/IL-12
treatment number affected CD3CCD8C infiltration in the bladder
and BDLNs (p < 0.05 via ANOVA), but not in the spleen.
Shifts in T-cell effector/memory phenotypes
We used CD44 and CD62L to monitor shifts in T-cell phenotypes.
CD44 is upregulated on effector (TEff), effector-memory (TEM),
and central memory (TCM) cells, and promote the genesis and sur-
vival of TH1 memory cells.
15 CD62L, also known as L-Selectin, is a
Figure 1. Immune cell depletion during treatment and rechallenge. (A) Mice were depleted of CD4C, CD8C, or NK1.1C lymphocytes prior to implantation of 75,000 MB49
cells in the bladder and throughout twice-weekly application of intravesical CS/IL-12 immunotherapy (arrows) begun 7 d post-implantation. Mice were monitored for
hematuria and survival. All CS/IL-12 treated groups, regardless of depletion status, significantly (p < 0.05) prolonged survival over PBS treated mice. (B) Mice which had
previously eradicated their tumors were depleted of CD4C, CD8C, or NK1.1C lymphocytes prior to subcutaneous rechallenge with 300,000 MB49 cells. Onset of tumor
growth was monitored and measured. With the exception of the CD4C depleted group all curves were significantly different (p< 0.05) than naive mice. Asterisks indicate
differences between groups determined via the log-rank test: p< 0.05 or p < 0.0005.
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surface receptor known to increase homing to secondary lymphoid
tissues and is associated with naive T cells (Tnaive) and TCM cells.
Although additional markers such as CD107 and CCR7 are often
included to get a more precise definition of memory phenotypes,
we chose a more general approach by monitoring shifts in popula-
tions defined as Tnaive (CD44
lowCD62LC), TEff (CD44lowCD62L¡),
TEM (CD44
highCD62L¡), and TCM (CD44highCD62LC) for both
CD4C (Fig. 5) and CD8C T cells (Fig. 6).16-18 The following
statistical comparisons refer to differences in the proportion of the
parent population (CD4C or CD8C T cells) between PBS and CS/
IL-12 treated mice at a given time point in the same tissue via Stu-
dent’s t-test or differences in those populations within the CS/IL-
12 treatment group with respect to treatment number determined
via one-way ANOVA.
CD4C T-cell effector/memory phenotypes
CD4C CD44lowCD62LC Tnaive cells were increased in the BDLNs
following the first treatment, but this difference was not sustained
after subsequent treatments (Fig. 5, first row). There was also a
general (but not significant) trend toward increased proportions
of Tnaive in the BDLNs for both CS/IL-12 and PBS treatments.
The proportion of CD4C bladder-infiltrating lymphocytes (BILs)
that were Tnaive cells remained small (< 15%) throughout the
treatments with a significantly (p < 0.05) smaller proportion in
the CS/IL-12 treatment group by the fourth treatment. There was
a 60% (p < 0.05) increase of Tnaive in the spleens of treated mice
after the second treatment when compared with PBS at the same
time point, but this difference was not maintained.
Figure 2. Number of treatments impact initial tumor rejection. (A) Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3, or 4 intravesical treatments with CS/
IL-12 on days 7, 11, 15, and 18, respectively. They were then tracked for hematuria and survival. (B) Survival curves from the same experiment as (A), but with the combined 1 and 2
treatments against the combined 3 and 4 treatments. Asterisks indicate differences between groups determined via the log-rank test: p< 0.05 or p< 0.0005.
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CD4C CD44lowCD62L¡ TEff cells began as the dominant
phenotype in both the BDLNs and spleen after the first
treatment, but decreased over time (Fig. 5, second row).
There was no difference in treatment groups in either the
spleen or BDLNs at any time point. However, there was a
decrease (p < 0.05) of TEff cells in CS/IL-12 treated blad-
ders versus PBS treated bladders after the fourth time point
as well as a trend toward fewer TEff over treatment number
in the spleen (p < 0.05 via ANOVA).
CD4C CD44highCD62L¡ TEM cells were the dominant
phenotype in the bladder comprising approximately 60% of
CD4C cells after the first CS/IL-12 treatment with a significant
climb (p < 0.05 via ANOVA) to 71% after the fourth treatment
(Fig. 5, third row). After the fourth treatment, there was also a
significant increase (p < 0.05) between treatment groups from
39.2% (PBS) to 71.4% (CS/IL-12). TEM infiltration in the
BDLNs or spleen was less pronounced throughout the duration
of treatment comprising 10–15% (BDLNs) and 20–30%
(spleen) of CD4C T cells. There was a higher (p < 0.05)
proportion of TEM in the BDLNs of PBS treated mice when
compared with CS/IL-12 treated mice after the second
treatment. There was also an increase (p < 0.05) in the spleens
of CS/IL-12 versus PBS treated mice, but the differences and
proportions remained small.
CD4C CD44highCD62LC TCM cells increased significantly
(p < 0.05) in proportion in the bladder after the first
Figure 3. Bladder weight decreases with treatment. Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3, or 4 intravesical treatments with CS/IL-
12 on days 7, 11, 15, and 18, respectively (n D 5–7 per group). One day after each treatment, the mice were sacrificed and their bladders were removed, weighed (A),
and photographed (B) before further processing for analysis. The representative bladders in (B) are placed on a 5.1-mm (0.2 in) grid paper. Error bars indicate mean with
SEM. Asterisks indicate differences between PBS and CS/IL-12 treated mice at the indicated time point as determined through Student’s t-test: p < 0.0005.
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treatment from PBS (9.1%) to CS/IL-12 (21.2%), but this
difference was not maintained after additional treatments
(Fig. 5, fourth row). Although there was a trend toward
increasing this population over time in both the spleen
(NS) and BDLNs (p < 0.05 via ANOVA), the total propor-
tion remained small (<10%) and there were no significant
differences between treatment types in these tissues.
Overall, treatment number and type impacted CD4C
memory phenotypes. CD4C T cells were characterized by
an early jump (treatments 1 and 2) in naive phenotypes at
systemic sites. This was followed by a late shift toward
effector/memory phenotypes after the fourth treatment both
in the bladder and in the spleen.
CD8C T-cell effector/memory phenotypes
CD8C CD44lowCD62LC Tnaive cells showed minimal varia-
tion by treatment type or number (Fig. 6, first row), but
did make up a large (40–60%) proportion of CD8C cells in
both the BDLNs and spleen. The sole significant difference
was a decrease (p < 0.05) in the spleen for treated mice
after the fourth treatment.
CD8C CD44lowCD62L¡ TEff cells were also present in large
(40–60%) proportions in both the BDLNs and spleen without
any significant differences between treatment groups (Fig. 6, sec-
ond row). They comprised a smaller portion (10–30%) of CD8C
cells in the bladder with an increased (p < 0.05) proportion for
PBS (26.4%) over treated (12.8%) mice after the fourth treatment.
There was also a significant effect (p < 0.05 via ANOVA) of CS/
IL-12 treatment number on TEff infiltration in the bladder.
CD8C CD44highCD62L¡ TEM cells were the largest (50–75%)
proportion of CD8C cells in the bladder with the proportion
in treated mice (73.8%) reaching significantly (p < 0.005)
higher than PBS (50.3%) after the fourth treatment (Fig. 6,
third row). Their proportion in the BDLNs and spleen were
smaller (5–15%) without any significant differences between
Figure 4. T-cell infiltration by treatment number and tissue. Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3, or 4 intravesical treatments with
CS/IL-12 or PBS on days 7, 11, 15, and 18, respectively (n D 4–5 per group). Bladder draining lymph nodes (BDLNs), bladders, and spleens were harvested 24 h after each
treatment and analyzed via flow cytometry. Error bars indicate mean with SEM. Asterisks indicate significant differences between PBS and CS/IL-12 treatment groups at
the same treatment number by Student’s t-test: p < 0.05 or p < 0.005.
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treatments types. However, there was a significant effect on
CS/IL-12 treatment number on TEM proportions in the
spleen (p < 0.05 via ANOVA).
CD8C CD44highCD62LC TCM cells exhibited little varia-
tion with treatment type in any of the tissues with the sole
significant difference between treatment types (p < 0.05) an
increase after the third treatment in the spleen (Fig. 6,
fourth row). There was, however, a significant effect of
treatment number on their proportion in the bladder (p <
0.005 via ANOVA). They consistently comprised a small
(5–20%) overall percentage of CD8C T cells in each tissue.
Overall, treatment number and type impacted CD8C
memory phenotypes. However, changes were only found in
the bladder and spleen, but not in the BDLNs. These effects
were characterized by a late shift (treatments 3 and 4)
toward effector/memory phenotypes.
Regulatory T-cells decline in the lymph nodes after the first
treatment
Differences in TRegs (CD3
CCD4CCD25CFoxp3C) were most
pronounced after the first treatment with a 30% decrease
(p <0.005) in the BDLNs. This was reflected in the CD8C:TReg
ratio as well, with ratios of 19 (PBS) and 29.7 (CS/IL-12). How-
ever, these differences were not sustained, nor were they found
in the bladder or spleen at any other time point. However, CS/
IL-12 treatment number did decrease infiltration in the spleen
(p < 0.05 via ANOVA), but not in the bladder or BDLNs.
Figure 5. CD4C T-cell effector/memory phenotypes by treatment number and tissue. Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3, or 4
intravesical treatments with CS/IL-12 or PBS on days 7, 11, 15, and 18, respectively (n D 4–5 per group). Bladder draining lymph nodes (BDLNs), bladders, and spleens
were harvested 24 h after each treatment and analyzed via flow cytometry. Error bars indicate mean with SEM. Asterisks indicate significant differences between PBS and
CS/IL-12 treatment groups at the same treatment number by Student’s t-test: p < 0.05.
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Natural killer cell infiltration is minimally affected
We identified natural killer (NK) cells as CD3¡CD49bC
leukocytes (Fig. 8, third row). Despite the depletion studies
(Fig. 1A) demonstrating a role for NK cells in tumor rejection,
we observed few significant differences in their infiltration with
treatment type or number. In the BDLNs, these changes
included a small increase after the first treatment as well as a
decrease (p < 0.05) after the fourth treatment. While in the
bladder, there was a small decrease after the first treatment in
CS/IL-12 versus PBS treated mice. Notably, the tumor itself
seemed to cause substantial NK infiltration as seen by the large
proportion of NK cells (»10%) in bladders of PBS treated
mice. While not assayed in the current study, the role of
CS/IL-12 may be to activate these resident NK cells in lieu of
increasing their infiltration.
Dendritic cell populations are minimally affected
To identify a potential source of antigen presenting cells
(APCs) as drivers of systemic immunity we gated on
GR1-MHCIICCD11CC dendritic cells (DCs) at each time point
(Fig. 6, first row). However, there were no obvious changes in
DC populations between treatment types with the exception of
a slight increase after the final treatment in the spleen for
CS/IL-12 versus PBS treated mice (p < 0.05). There was also a
significant (p < 0.05 via ANOVA) increase in DC infiltration
Figure 6. CD8C T-cell effector/memory phenotypes by treatment number and tissue. Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3, or 4
intravesical treatments with CS/IL-12 or PBS on days 7, 11, 15, and 18, respectively (n D 4–5 per group). Bladder-draining lymph nodes (BDLNs), bladders, and spleens
were harvested 24 h after each treatment and analyzed via flow cytometry. Error bars indicate mean with SEM. Asterisks indicate significant differences between PBS and
CS/IL-12 treatment groups at the same treatment number by Student’s t-test: p < 0.05 or p < 0.005.
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in the BDLNs with respect to treatment number. Overall,
CS/IL-12 had minimal effects on DC infiltration.
Macrophages drive initial infiltration and are likely
sources of antigen presentation
Another possible source of antigen presentation, macrophages
(GR1¡F4/80C) were significantly (p < 0.05) increased in the
bladder following the first treatment with 26.0% (CS/IL-12)
and 16.8% (PBS) of all live leukocytes staining as macrophages
(Fig. 8, second row). There was also an up to 2-fold increase of
macrophages in the spleens of CS/IL-12 versus PBS treated
mice that was sustained after the second treatment. There was
also a significant increase (p < 0.05 via ANOVA) of
macrophages in the spleen with treatment number. Overall,
CS/IL-12 caused early macrophage infiltration in the bladder,
later infiltration in the spleen, and no effects on macrophages
in the BDLNs.
MDSCs decline in the bladders of treated mice
We were also curious about the role of GR1CCDllbC MDSCs
on tumor rejection or growth (Fig. 8, third row). We found that
MDSCs were very prevalent in the bladder tumors, comprising
more than 50% of all live cells in the case of some PBS treated
tumors. We found that levels of MDSCs in CS/IL-12 treated
mice seemed to increase in all tissues after the initial treatment
though not in a statistically significant manner. There was a
significant effect (p < 0.05 via ANOVA) of treatment number
on MDSC infiltration in the bladder. This was coupled with a
decrease in MDSCs in the bladder for CS/IL-12 versus PBS
treated mice after the third(p < 0.0005) and fourth (p < 0.05)
treatments with levels reaching less than a third of those in PBS
treated mice. By the fourth treatment, there was also a 3-fold
increase (p < 0.05) of MDSCs in the spleen, although the over-
all percentage remained small. There was no significant effect
of treatment number or type on MDSCs in the BDLNs. Overall,
CS/IL-12 caused a substantial depopulation of MDSCs in the
bladder, a small uptick of MDSCs in the spleen, and did not
impact MDSCs in the BDLNS.
Discussion
These are the first studies to elucidate the local and systemic
immunological mechanisms of intravesical IL-12-based
immunotherapy. Our depletion studies (Fig. 1A) demonstrated
Figure 7. Regulatory T-cell and natural killer cell infiltration by treatment number and tissue. Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3,
or 4 intravesical treatments with CS/IL-12 or PBS on days 7, 11, 15, and 18, respectively (nD 4–5 per group). Bladder draining lymph nodes (BDLNs), bladders, and spleens
were harvested 24 h after each treatment and analyzed via flow cytometry. Error bars indicate mean with SEM. Asterisks indicate significant differences between PBS and
CS/IL-12 treatment groups at the same treatment number by Student’s t-test: p < 0.005.
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the importance of cytotoxic CD8C effector cells in eliminating an
initial bladder tumor, a finding that is unsurprising as cytotoxic
T cells are known to directly engage tumor cells. However, dis-
tant (subcutaneous) rechallenge of previously treated mice which
had eliminated their orthotopic tumors revealed that CD4C
helper T cells are vital for protective systemic memory (Fig. 1B).
Indeed, these cells were able to eradicate new tumors even dur-
ing depletion of cytotoxic T cells.
While surprising at first glance, antitumor CD4C helper
T cells activity has been demonstrated previously, although
their role as antitumor immune cells is still being
unraveled.19,20 It has been established that CD4C T cells help
recruit and activate tumor specific CD8C T cells and promote
their survival,16,21,22 but studies have also begun to show the
ability of CD4C T cells to kill tumor cells in the absence of
CD8C T cells.20 One example related to our current study
showed that adoptively transferred, monoclonal, antigen-
specific CD4C T cells were more efficient than CD8C T cells at
rejecting subcutaneous MB49 bladder tumors, even when the
tumors did not express MHC-II.23 That study also identified
NK cells as important effectors in the absence of CD8C T cells.
However, unlike our own study and likely due to limitations of
their model system, they did not demonstrate the role of CD4C
cells in a memory response, nor in an orthotopic model. Thus
our study provides additional evidence into the important role
that CD4C cells play in antitumor immunity and in memory.
However, the mechanistic way in which they do so has not
been fully explored here and should be the subject of future
investigations.
The second question we addressed was the role of the number
of treatments on successful therapy. Somewhat surprisingly, we
found that even a single treatment was effective at eliminating
tumors in 50% of mice, but it required 3 or 4 treatments to reach
higher levels of cure (Fig. 2). Nonetheless, four treatments are a
vast improvement over BCG, the current standard of care, which
shows no efficacy against MB49 after four treatments7 and in the
clinic maximal efficacy, requires an induction course of 6 weekly
treatments followed by 7 maintenance courses of 3 applications
each for a total of 27 applications.24
Building upon those results we asked our third major question:
how are immune cell kinetics within the tumor and in secondary
lymphoid organs affected by each treatment. This is not the first
Figure 8. Myeloid cell infiltration by treatment number and tissue. Mice were implanted with 75,000 MB49 cells in the bladder and given 1, 2, 3, or 4 intravesical treat-
ments with CS/IL-12 or PBS on days 7, 11, 15, and 18, respectively (n D 4–5 per group). Bladder draining lymph nodes (BDLNs), bladders, and spleens were harvested
24 h after each treatment and analyzed via flow cytometry. Error bars indicate mean with SEM. Asterisks indicate significant differences between PBS and CS/IL-12 treat-
ment groups at the same treatment number by Student’s t-test: p< 0.05 or p < 0.0005.
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study to investigate the immune infiltration of tumors caused by
an IL-12-based treatment, but it is the first to do so in a quantita-
tive manner using an orthotopic model of bladder cancer and the
first to look at the infiltration over the course of multiple
treatments.8,9,11,12,25 Our investigation revealed a role for each of
the treatments in reversing immunosuppression and promoting a
long-term immune response.
The first treatment was found to be critical for inducing
macrophage and granulocyte inflammation, reducing TReg
infiltration in the BDLNS, and increasing the CD8C:TReg ratio
in the BDLNs (Fig. 7). Curiously, the first treatment also
demonstrated increased infiltration of TCM CD4
C T cells in the
bladder perhaps as an augmentation of the resident TCM
population induced by MB49 implantation. The second
treatment appeared to be a turning point of sorts at which
several populations were in flux, but with a few detectible shifts
in populations. At this stage, cells appeared ready to divide and
infiltrate (as seen through increased na€ıve CD4C T cells in
Fig. 5) while macrophage expansion occurs in the spleen
(Fig. 8). After the third treatment, the differences in immune
infiltration become more apparent with increased CD4C and
CD8C T-cell infiltration in the bladder (Fig. 4) as well as
decreased MDSC infiltration (Fig. 8). Changes on the periphery
included increased CD8C T cells in the BDLNs coupled by a
decrease of T cells in the spleen, possibly a result of their
exfiltration to the tumor site as effectors (Fig. 4). The fourth
treatment seemed to solidify the change from an immunosup-
pressive to an active phenotype. In the bladder, this change was
characterized by most immune cells becoming effector-
memory T cells (Figs. 5 and 6) with minimal lingering innate
inflammation (Fig. 8). In the BDLNs, it was shown by
continued naive/effector CD8C T-cell infiltration, whereas in
the spleen it was evidenced by increased macrophages, DCs,
and granulocytes (Fig. 8) as well as a shift in CD4C cells to an
effector-memory phenotype (Fig. 5).
Although this study has added to the understanding of
intravesically delivered IL-12 immunotherapies, it does have
limitations. First, in order to plumb the depths of immune cell
changes, we focused on a single tumor model. Future studies
ought to explore immune infiltration in additional orthotopic
tumor models and in additional species. Second, this study
focused on immune cell phenotype and not on function. Future
studies ought to investigate cytokine release, antigen presenta-
tion, and cellular activation. This is especially true in the case
of NK cells, which were not shown in this current study to
infiltrate into the bladder in response to CS/IL-12, but did play
a role in therapy during depletion studies and comprised a
substantial population in the bladder even in the absence of
therapy. Third, we did not look at immune populations in the
blood which could be useful as a more clinically palatable
monitor of treatment efficacy. Fourth, the current study
suggests that treatments with CS/IL-12 have effects long after
their initial application as evidenced by the delay in tumor
weight (Fig. 3) in relation to survival benefit (Fig. 2) as well as
the surprising effectiveness of a single CS/IL-12 treatment.
Thus, this study opens the potential for additional
investigations into the state of bladder tumor suppression,
tumor escape, and immune cell fluctuations after a single treat-
ment of CS/IL-12.
Nevertheless, this study provides another stepping stone on
the path to IL-12-based immunotherapies for bladder cancer.
The current studies could provide the basis for correlative
studies in planned Phase I and II clinical trials. Likely readouts
would include a shift in the CD8C:TReg ratio from a draining
lymph node (or potentially blood), or a demonstrated increase
in macrophage infiltration in the bladder tumor after the first
treatment with continued monitoring of T-cell infiltration
throughout treatment.
Methods
Animals, materials, and cell lines
The University of Arkansas Institutional Animal Care and Use
Committee approved of all animal protocols in compliance
with The Guide for Care and Use of Laboratory Animals
(National Research Council). Female C57BL/6J mice were
purchased from Jackson Laboratory, housed in microisolator
cages, and placed on study at 9–15 weeks of age.
Dulbecco’s Phosphate Buffered Saline (DPBS), Roswell Park
Memorial Institute Medium (RPMI), Dulbecco’s Modified Eagle’s
Medium (DMEM), and Fetal Bovine Serum (FBS) were purchased
from HyClone Laboratories. Chitosan glutamate (Protosan G213,
200–600 kDa, 75–90% deacetylated) was obtained from Novama-
trix (4210306). Recombinant murine IL-12 was provided by the
University of Arkansas Biologics Center. Triple enzyme digestive
solution was prepared from collagenase type IV (10 mg/mL, MP
Biomedicals, 0219511090), Hyaluronidase (1 mg/mL, MP
Biomedicals, 0210074080), and DNase I (200 mg/ml, VWR,
97062-108) in Hanks Balanced Salt Solution (Corning). Lympho-
lyte-M was obtained from CedarLane (CL5031).
MB49, a C57BL/6 syngeneic transitional cell carcinoma, was
kindly provided by Dr. Jeffrey Schlom, Laboratory of Tumor
Immunology and Biology, National Cancer Institute. MB49 was
maintained in DMEM supplemented with 10% FBS, 2 mM L-
glutamine, and 1% penicillin/streptomycin. Complete media for
the culture of cells isolated from tissues was composed of RPMI
supplemented with 10% FBS, 2mM b-Mercaptoethanol (55
mM), penicillin/streptomycin (100 U/mL), L-glutamine (2 mM),
Sodium Pyruvate (1 mM), and non-essential amino acids.
Tumor model and therapy
Orthotopic bladder tumors were implanted via intravesical
instillation of 75,000 MB49 cells as described previously.7 Intra-
vesical tumor burden was monitored by development of hema-
turia and palpable tumors. Intravesical treatments were given
using the same catheterization technique. Briefly, the therapy
was prepared by first dissolving chitosan glutamate in DPBS at
10 mg/mL in a shaker (1400 RPM, 55 C, 1 h) and then adding
IL-12 to a final concentration of 10 mg/mL. The mice were
catheterized and 100 mL of therapy allowed to dwell for 35–
45 min. All administration of CS/IL-12 described in this manu-
script consisted of a 1 mg dose of IL-12.
All subcutaneous implantations were of 300,000 MB49 cells
administered in the right flank and the tumor volume calcu-
lated as Volume D 0.5Length Width.2Mice were euthanized
when moribund or when tumor volume reached 2,000 mm3.
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Depletion studies
Depletion antibodies for CD4C (BE0003), CD8C (BE0061), or
NK1.1 (BE0036) were obtained from BioXCell. Mice were
depleted prior to starting the experiment via four once-daily
administrations of 100 mg depletion antibodies given intraperi-
toneally. This depletion was maintained throughout the study
by twice weekly administrations of 100 mg of antibody. The
depletion protocol was verified via flow cytometry (Fig. S1).
Tissue homogenization and flow cytometry
Bladder tumors, BDLNs, and spleens were obtained for single
cell analysis of immune cell infiltrates via flow cytometry.
Bladder and tumor tissues were weighed and imaged before
being cut into small pieces in RPMI, allowed to digest in triple
enzyme concoction for 30 min at 37 C, passed through a
60-mm filter, separated via a Lympholyte gradient, and sub-
jected to ACK lysis prior to staining. BDLNs were taken to be
the lumbar lymph nodes.26 The spleen as well as the BDLNs
were harvested into complete media and homogenized using
the 60-mm filter. Splenocytes were also subjected to an ACK
lysis step. Prior to staining, cell concentrations and numbers
were determined via a manual hemacytometer.
Cells were stained with a fixable live/dead discriminator,
treated with FC Block (BD 553142), and then surface stained
with pre-titrated amounts of antibodies prior to fixation,
permeabilization, and intracellular staining. Fixation/permeabi-
lization was implemented with either BD Fix/Perm (5230583)
or for panels containing FoxP3 BD Fix/Perm TF (562574).
Samples were then acquired on a Becton Dickinson (Franklin
Lakes, NJ) FACSCanto II cytometer equipped with red (633
nm) and blue (488 nm) lasers. Data analysis was performed
using FlowJo (Ashland, Oregon).
All antibodies and stains were purchased from Becton
Dickinson: Live/Dead fixable viability dye-FITC (564407),
CD3-PE (553064), CD4-PE-Cy7 (552775), CD8-Percp-Cy5.5
(551162), CD44-APC (559250), CD62L-APC-Cy7 (560514),
CD49b-APC (560628), CD25-APC-Cy7 (557658), FoxP3-
PerCp-Cy5.5 (563902), GR-1-PE-Cy7 (560601), F4/80-PE
(565410), CDllb-APC-Cy7 (557657), CDllc-APC (550261), and
I-A/I-E-Percp-Cy5.5 (562363). Overall, analysis was performed
on three panels (Fig. S2) as well as isotype controls (Fig. S3)
and fluorescence minus-one (FMO) controls for CD44 and
CD62L (Fig. S3).
Statistical analysis
Data was plotted and statistical analysis performed with
Graphpad Prism with data pre-processing implemented in
MATLAB. For survival curves, significance was determined via
the log-rank test. An unpaired Student’s t-test was used to
compare PBS and CS/IL-12 treatments at each time point for
bladder weights and immunophenotyping studies. An ordinary
one-way ANOVA was used to examine the effects of CS/IL-12
treatment number on immunophenotypes. Significance levels
denoted as not significant (NS), p < 0.05, p < 0.005, or
p < 0.0005.
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